Thomas-Paul Descamps

TP has a significant track record in pharmaceutical and biotech companies. He has worked in different business cultures (Europe & US) and various Therapeutic Areas ranging from wide markets - such as anti-infective - to Rare Diseases. His commercial and portfolio management expertise has been gained from big pharma and start-ups in the biotech world. TP offers a great capability to bridge advanced science with business needs. As a general manager he covers a wide array of skills and he likes to create and lead teams to generate results and to develop and build crosscutting strategies with a strong focus on implementation. In addition, his network and ability to raise funds has been instrumental to the recent financing rounds and will help a lot to fuel Jellagen’s future growth.

TP Holds a Master's Degree in General Management from the University Paris IX Dauphine and a Diploma in Finance and Marketing from Sciences-Po Paris. Since 1993 he has held many positions in Sales and Marketing with global pharmaceutical players such as GSK and Eli Lilly.

In 2004, he joined Actelion -a rare disease fast growing Pharmaceutical company- where as Director Commercial Operations he successfully set up the commercial team of the French affiliate, achieving best worldwide sales per Million Inhabitants. In 2008 he broadened his expertise in Joining Ipsen as a VP in charge of the Neurology Global portfolio management, including Franchise strategy, Product Clinical Development, Business Development etc. In 2011 he successfully expanded an Ipsen US acquisition Start-Up in Europe, achieving 6 countries opening in 6 months.

In 2013 he took up an offer to move to London to join Allergan in a European Commercial role before moving in 2015 to a French mid-size pharma company as VP of Europe. Since 2014 TP has also acted as a Business angel. He helped raise >£4M for Jellagen during the two last rounds and is an investor and Chairman of the board at Histide, a Swiss Biotech Start-Up. In April 2016, Thomas-Paul [TP] was appointed as a Senior Adviser to the CEO of Jellagen, and Board Observer. In April 2018 he has been appointed as CEO, Executive Director and Member of Jellagen’s Board.